Scancell Holdings plc (SCNLF)
USD 0.1
(-57.02%)
USD 0.1
(-57.02%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -11.92 Million GBP | 10.37% |
| 2022 | -13.29 Million GBP | -50.54% |
| 2021 | -8.83 Million GBP | -30.26% |
| 2020 | -6.78 Million GBP | -0.79% |
| 2019 | -6.72 Million GBP | -36.17% |
| 2018 | -4.94 Million GBP | -8.64% |
| 2017 | -4.54 Million GBP | -49.48% |
| 2016 | -3.04 Million GBP | -2.81% |
| 2015 | -2.95 Million GBP | -18.53% |
| 2014 | -2.49 Million GBP | -14.34% |
| 2013 | -2.18 Million GBP | -11.34% |
| 2012 | -1.96 Million GBP | -13.12% |
| 2011 | -1.73 Million GBP | 3.93% |
| 2010 | -1.8 Million GBP | -102.58% |
| 2009 | -891 Thousand GBP | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -4.05 Million GBP | 13.16% |
| 2024 Q2 | -4.05 Million GBP | 0.0% |
| 2023 Q3 | -4.97 Million GBP | 31.36% |
| 2023 FY | -11.92 Million GBP | 10.37% |
| 2023 Q1 | -987 Thousand GBP | 88.14% |
| 2023 Q2 | -7.24 Million GBP | -634.04% |
| 2023 Q4 | -4.67 Million GBP | 5.99% |
| 2022 Q2 | -5.94 Million GBP | -120.39% |
| 2022 FY | -13.29 Million GBP | -50.54% |
| 2022 Q4 | -8.31 Million GBP | -87.6% |
| 2022 Q3 | -4.43 Million GBP | 25.41% |
| 2022 Q1 | -2.69 Million GBP | 60.18% |
| 2021 Q2 | -2.97 Million GBP | -100.0% |
| 2021 Q4 | -6.77 Million GBP | -100.0% |
| 2021 Q3 | -3.38 Million GBP | -13.79% |
| 2021 Q1 | -1.48 Million GBP | 59.68% |
| 2021 FY | -8.83 Million GBP | -30.26% |
| 2020 FY | -6.78 Million GBP | -0.79% |
| 2020 Q3 | -1.84 Million GBP | 40.26% |
| 2020 Q4 | -3.69 Million GBP | -100.0% |
| 2020 Q2 | -3.08 Million GBP | -99.99% |
| 2020 Q1 | -1.54 Million GBP | -1.24% |
| 2019 Q1 | -1.83 Million GBP | -43.92% |
| 2019 FY | -6.72 Million GBP | -36.17% |
| 2019 Q2 | -1.83 Million GBP | 0.0% |
| 2019 Q3 | -1.52 Million GBP | 16.99% |
| 2019 Q4 | -1.52 Million GBP | 0.0% |
| 2018 Q2 | -1.19 Million GBP | 0.0% |
| 2018 Q4 | -1.27 Million GBP | 0.0% |
| 2018 Q1 | -1.19 Million GBP | 2.09% |
| 2018 FY | -4.94 Million GBP | -8.64% |
| 2018 Q3 | -1.27 Million GBP | -7.03% |
| 2017 Q4 | -1.21 Million GBP | 0.0% |
| 2017 Q1 | -1.05 Million GBP | -25.99% |
| 2017 Q2 | -1.05 Million GBP | 0.0% |
| 2017 Q3 | -1.21 Million GBP | -15.5% |
| 2017 FY | -4.54 Million GBP | -49.48% |
| 2016 FY | -3.04 Million GBP | -2.81% |
| 2016 Q2 | -683.88 Thousand GBP | 0.0% |
| 2016 Q3 | -837.69 Thousand GBP | -22.49% |
| 2016 Q4 | -837.69 Thousand GBP | 0.0% |
| 2016 Q1 | -683.88 Thousand GBP | 2.24% |
| 2015 Q2 | -780.4 Thousand GBP | 0.0% |
| 2015 Q3 | -699.59 Thousand GBP | 10.36% |
| 2015 FY | -2.95 Million GBP | -18.53% |
| 2015 Q1 | -780.4 Thousand GBP | -31.09% |
| 2015 Q4 | -699.59 Thousand GBP | 0.0% |
| 2014 Q3 | -595.33 Thousand GBP | 8.87% |
| 2014 Q1 | -653.27 Thousand GBP | -9.43% |
| 2014 Q4 | -595.33 Thousand GBP | 0.0% |
| 2014 FY | -2.49 Million GBP | -14.34% |
| 2014 Q2 | -653.27 Thousand GBP | 0.0% |
| 2013 Q4 | -597 Thousand GBP | 0.0% |
| 2013 FY | -2.18 Million GBP | -11.34% |
| 2013 Q3 | -597 Thousand GBP | 0.0% |
| 2012 FY | -1.96 Million GBP | -13.12% |
| 2011 FY | -1.73 Million GBP | 3.93% |
| 2010 FY | -1.8 Million GBP | -102.58% |
| 2009 FY | -891 Thousand GBP | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.25 Million USD | -849.045% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 78.526% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 114.563% |
| Nascent Biotech, Inc. | -2.22 Million USD | -434.558% |
| Qrons Inc. | -643.67 Thousand USD | -1751.86% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -2768.978% |
| Adynxx, Inc. | - USD | Infinity% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -136.298% |
| BioStem Technologies, Inc. | -7.77 Million USD | -53.234% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 33.21% |
| Skye Bioscience, Inc. | -13.67 Million USD | 12.813% |
| Rebus Holdings, Inc. | -664 Thousand USD | -1695.181% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -792.596% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -2959.784% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 24.888% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 83.395% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 342.532% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -4454.381% |
| SQZ Biotechnologies Company | -75.82 Million USD | 84.28% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -318.171% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -676.017% |
| Mesoblast Limited | -84.14 Million USD | 85.834% |
| Marizyme, Inc. | -34.08 Million USD | 65.03% |
| Genus plc | 6.4 Million USD | 286.25% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 222.351% |
| Pharming Group N.V. | -4.87 Million USD | -144.285% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -500.057% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -1179.821% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -42.754% |
| ContraFect Corporation | -56.88 Million USD | 79.047% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -161.706% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -750.219% |
| IMV Inc. | -38.67 Million USD | 69.176% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -333.322% |
| MultiCell Technologies, Inc. | -722.81 USD | -1649019.409% |
| ONE Bio Corp. | 13.68 Million USD | 187.125% |
| Accustem Sciences Inc. | -3.74 Million USD | -218.17% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 79.793% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -2367.592% |
| Q BioMed Inc. | -3.44 Million USD | -245.947% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 436.723% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -353.659% |
| Biomind Labs Inc. | -1 Million USD | -1080.662% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 78.316% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -310.857% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -79.302% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -539.358% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -39697.009% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -516.782% |
| GB Sciences, Inc. | -1.42 Million USD | -739.136% |
| Alpha Cognition Inc. | -9.7 Million USD | -22.816% |
| HST Global, Inc. | -140.9 Thousand USD | -8359.48% |
| CSL Limited | 3.7 Billion USD | 100.322% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -959.644% |
| Halberd Corporation | -75.05 Thousand USD | -15782.745% |
| Enzolytics Inc. | -2.14 Million USD | -454.728% |
| Agentix Corp. | -1.37 Million USD | -768.959% |
| Resverlogix Corp. | -12.74 Million USD | 6.502% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -276.23% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 97.196% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -1041.762% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -308.297% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -654.738% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -250.076% |
| AVAX Technologies, Inc. | 6.69 Million USD | 278.1% |
| Zenith Capital Corp. | -8.94 Million USD | -33.289% |
| Genscript Biotech Corporation | -415.79 Million USD | 97.133% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -68323.167% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -385.477% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -6850.051% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -494.586% |
| Kadimastem Ltd | -3.04 Million USD | -292.073% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -1111.317% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -6468.036% |
| LadRx Corporation | -3.82 Million USD | -211.746% |
| Cell Source, Inc. | -4.32 Million USD | -175.585% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1635.206% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -1635.206% |
| NovAccess Global Inc. | -2.46 Million USD | -383.225% |
| Affymax, Inc. | -15.04 Million USD | 20.776% |
| Itoco Inc. | -919.14 Thousand USD | -1196.864% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -181.237% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -965.237% |
| Mobile Lads Corp. | -554.55 Thousand USD | -2049.491% |
| CytoDyn Inc. | -18.05 Million USD | 33.99% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -47257.966% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -5316.262% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -2010.769% |
| SYBLEU INC | -149.18 Thousand USD | -7890.347% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -556.272% |
| International Stem Cell Corporation | -663 Thousand USD | -1697.888% |
| Bioxytran, Inc. | -3.82 Million USD | -212.03% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -22544.377% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -58503.736% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 67.132% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -636.712% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -1519.928% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -283.157% |
| Neutra Corp. | -229.48 Thousand USD | -5094.217% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 32.037% |
| PureTech Health plc | -146.19 Million USD | 91.847% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 44.535% |
| IXICO plc | -1.43 Million USD | -729.506% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -25.593% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 90.214% |
| CSL Limited | 3.81 Billion USD | 100.313% |
| Cellectis S.A. | -108.85 Million USD | 89.05% |